AZ Looks To Lead Severe Asthma Market After US Fasenra OK

 
• By Kevin Grogan

Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.

Speedway
AstraZeneca joins the severe asthma race with the US approval of Fasenra • Source: Shutterstock

More from Respiratory

More from Therapy Areas